Health Populi

MARCH 11, 2021

[Note: I may be biased as a University of Michigan graduate of both the School of Public Health and Rackham School of Graduate Studies in Economics]. health care, patient assistance programs, Medicare Advantage plans, and the bundling of proven high-value preventive services into the Affordable Care Act.

Health Policy 245

Health Policy Medicare Pharmaceuticals Life Science 245

Health Populi

JUNE 24, 2021

I welcomed the opportunity to learn from this team’s approach in weaving together the dynamic issues that help us to plan for the long-tail of COVID-19 and its impact on the economy and prospects for the health care industry and health citizens. spends on NASA.

BioTech 270

BioTech Pharmaceuticals Public Health Telehealth 270

Health Populi

OCTOBER 28, 2019

Hospital costs contribute to rising medical costs to 49% of health consumers. patients’ negative views of the pharmaceutical industry in this study was the opioid epidemic. A recent study on politics and health care spending in the U.S. Physician fees are cited as cost-contributing by only 18% of patients.

Pharmaceuticals 136

Pharmaceuticals Medical Billing Medicare Mental health 136

Health Populi

MAY 8, 2019

In 2018, we saw more incentives to inspire adherence to prescription drug regimens, particularly in Medicare Part D along with increasing focus by pharmacists and providers. Just under 9% of patients across all three health plan types had over $500 in OOP costs in 2018. A cost of $125 or more yields abandonment of at least 50%.

Medicare 149

Medicare BioTech Pharmaceuticals Mental health 149

Health Populi

AUGUST 16, 2021

There is one health care public policy issue that unites U.S. voters across political party: that is the consumer-facing costs of prescription drugs.

Pharmaceuticals 323

Pharmaceuticals Telehealth BioTech Mental health 323

Health Populi

MARCH 6, 2019

is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. One of the only issues bringing people together in the U.S. ” drugs to come to market, understanding this dynamic.

Pharmaceuticals 140

Pharmaceuticals Life Science Medicare BioTech 140

Health Populi

MAY 19, 2019

They don’t tend to shop around for health care or be super-engaged in their care, probably because they tend to be older and more likely to be covered by Medicare. They may be threatened by a call for “Medicare for All” given their affection for the program. That’s an interesting conundrum to consider.

Life Science 149

Life Science BioTech Medicare Medical Billing 149